Endologix (ELGX) has an appealing product pipeline in the field of Endovascular aortic repair, or EVAR. Its innovative products such as AFX, Nellix, and Ventana have the potential to grow its EVAR segment substantially. According to Endologix, around 63,000 abdominal aortic aneurysm, or AAA repairs were done in 2012; out of those, 75% were EVAR procedures and 25% were open surgery procedures. This depicts the dominance of EVAR in treating AAA and thus opens a significant opportunity for Endologix to excel in the field of EVAR. Further, it has an impressive historical (2008-2012) track record of driving consistent 20% plus revenue growth. Over the past three years, it has achieved a remarkable CAGR of 26%.
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: